Furthermore, the use of bisphosphonates and the RANKL inhibitor denosumab, potent inhibitors of bone resorption, represents the major treatment and prevention strategy for PCa bone metastasis, which underscores the notion that osteoclast differentiation cannot be ignored in the development of the disease. Here, TNFSF11 is linked to posterior cortical atrophy.